{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060199","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.745583+00:00","generated_at":"2026-06-02T02:13:53.966712+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Leap Therapeutics reports Q1 2024 net loss of $13.8M; completes $40M private placement","bullets":["Net loss of $13.8M for Q1 2024 vs $41.9M Q1 2023; decrease due to $29.6M IPR&D expense from Flame merger in prior year.","Completed $40M private placement with Gilead and other investors; net proceeds $37.2M extend cash runway into Q2 2026.","Expanded Part B of DeFianCe CRC study from 130 to 180 patients; enrollment expected late Q3/Q4 2024, data mid-2025.","Part C of DisTinGuish GEJ/gastric cancer study fully enrolled (170 patients); initial data expected H2 2024 or early 2025.","Cash and equivalents $54.9M at March 31, 2024; exclusive of April 2024 private placement proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060199","json":"https://secwatch.observer/filing/0001104659-24-060199.json","markdown":"https://secwatch.observer/filing/0001104659-24-060199.md","text":"https://secwatch.observer/filing/0001104659-24-060199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924060199/0001104659-24-060199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924060199/tm2414104d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:13:53.966712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4844a58f72df9a80af9bac922d337bc3349a4e93","claim":"CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2024 results: net income $13.8 million.","evidence_excerpt":"Net Loss was $13.8 million for the first quarter 2024, compared to $41.9 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924060199/0001104659-24-060199-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$13.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}